Glibenclamidum

General characteristics. Structure:

Active agent: Glibenclamidum of 5 mg.

Pharmacological properties:

Peroral hypoglycemic means derivative of generation sulphonylurea II. Stimulates insulin secretion with pancreas β-cells, increases insulin release. Works mainly during the second stage of secretion of insulin. Increases sensitivity of peripheral fabrics to insulin and extent of its linkng with target cells. Has hypolipidemic effect, reduces thrombogenic properties of blood.

Pharmacokinetics. After intake Glibenclamidum is quickly and almost completely soaked up from a GIT. Linkng with proteins of plasma makes more than 95%. It is metabolized in a liver with formation of inactive metabolites.
It is brought out of an organism generally in the form of metabolites with urine - 95% and with bile. T1/2 is about 10 h.

Indications to use:

Diabetes mellitus 2 types at adults at inefficiency of a dietotherapy.

Route of administration and doses:

The dose is established individually, depending on age, by severity of diabetes, glycemia level on an empty stomach and in 2 h after food.
The average dose makes 2.5-15 mg/days, reception frequency - 1-3 times/days. Accept in 20-30 min. prior to food. In doses more than 15 mg/days are used in rare instances and does not cause essential strengthening of hypoglycemic effect.
For elderly patients the initial dose makes 1 mg/days.
Upon transition from guanyl guanidines the initial dose of Glibenclamidum makes 2.5 mg/days. Guanyl guanidines should be cancelled, and Glibenclamidum dose if necessary can be raised on 2.5 mg each 5-6 days to compensation of disturbances of carbohydrate metabolism. In the absence of compensation within 4-6 weeks it is necessary to plan a combination therapy glibenclamide and guanyl guanidines.

Features of use:

With care apply at patients with pathology of a liver and kidneys (including in the anamnesis), and also at feverish conditions, dysfunctions of adrenal glands, a thyroid gland, at an alcoholism.
During therapy regular control of content of glucose in blood and daily excretion of glucose with urine is necessary.
At development of a hypoglycemia if the patient is in consciousness, glucose (or sugar solution) is appointed inside. At a loss of consciousness enter glucose in/in or a glucagon п / to, in oil or in / century. After recovery of consciousness it is necessary to give to the patient food, carbohydrate-rich, in order to avoid repeated development of a hypoglycemia.
The patients accepting Glibenclamidum should abstain from alcohol intake. In case of alcohol intake development of disulfiramopodobny reactions, and also the expressed hypoglycemia is possible.

Side effects:

- From endocrine system: a hypoglycemia up to a coma (the probability of its development increases at disturbance of the mode of dosing and an inadequate diet).
- Allergic reactions: skin rash, itch.
- From the alimentary system: nausea, diarrhea, feeling of weight in the field of an epigastrium; seldom - abnormal liver functions, a cholestasia.
- From TsNS and a peripheral nervous system: seldom - paresis, sensitivity disturbances, a headache, fatigue, weakness, dizziness.
- From system of a hemopoiesis: seldom - disturbances of a hemopoiesis up to development of a pancytopenia.
- Dermatological reactions: seldom - a photosensitization.

Interaction with other medicines:

Strengthening of hypoglycemic effect of glibenclamide is possible at simultaneous use of beta adrenoblockers, anabolic means, Allopyrinolum, Cimetidinum, Clofibratum, cyclophosphamide, Isobarinum, MAO inhibitors, sulfonamides of long action, salicylates, chloramphenicol, tetracyclines, etanolsoderzhashchy drugs.

Weakening of effect of glibenclamide and development of a hyperglycemia is possible at simultaneous use of barbiturates, Chlorpromazinum, fenotiazin, Phenytoinum, diazoxide, acetazoleamide, glucocorticoids, sympathomimetic means, a glucagon, indometacin, high doses of nikotinat, contraceptives for intake and estrogen, saluretics, hormones of a thyroid gland, salts of lithium, high doses of purgatives.

Contraindications:

Diabetes mellitus of 1 type, ketoacidosis, diabetic prekoma and coma, heavy disturbances of microcirculation, infectious diseases, the expressed renal failures and/or a liver. Hypersensitivity to derivatives of sulphonylurea and sulfanamide drugs. Do not apply when carrying out serious surgical interventions.

Use at pregnancy and feeding by a breast
Glibenclamidum is not recommended to be applied at pregnancy and in the period of a lactation.

Use at abnormal liver functions
It is contraindicated at the expressed abnormal liver functions. With care apply at patients with liver pathology (including in the anamnesis).

Use at renal failures
It is contraindicated at the expressed renal failures. With care apply at patients with pathology of kidneys (including in the anamnesis).

Use for elderly patients
For elderly patients the initial dose makes 1 mg/days.

Overdose:

There are no data.

Storage conditions:

List B. In the place protected from light.

Issue conditions:

According to the recipe

Packaging:

Tablets of 5 mg: 50 pieces.